Does Wegovy 1mg Work at That Dose?

The decision most people face at 1mg: is this working, or should I push higher?

A question our prescribers hear most weeks goes something like this: "I've just moved to 1mg and I'm not sure I feel much different, is it doing anything?" The honest answer is that 1mg semaglutide is biologically active. GLP-1 receptors are responding. Gastric emptying is slower than it was before treatment. But the dose is still climbing toward the level where the NHS medicines guidance on semaglutide describes the fullest clinical effect.

The 1mg step is the midpoint of the titration, not the destination. You have been on 0.25mg and 0.5mg before this, and you will go to 1.7mg and then 2.4mg. That full arc across roughly five months is by design. If you are at 1mg and seeing some appetite reduction, some weight movement, that is the treatment functioning correctly at this stage. If you have seen nothing at all, that is worth raising with your prescriber, because it may influence the pace or the plan.

The key decision here is not whether to stop or accelerate; it is to stay in conversation with your prescribing team about how your body is responding at each step. For more on how the whole titration is structured, the piece on how Wegovy's dosage works walks through the logic behind each rung.

What the evidence shows about lower doses in the schedule

The STEP 1 trial did not measure 1mg as a standalone endpoint, semaglutide's clinical development programme built toward 2.4mg as the target maintenance dose, and that is the dose at which the trial's headline ~15% average weight reduction over 68 weeks was observed. Lower doses along the way were never designed to be the therapeutic ceiling.

That said, there is real biological activity at 1mg. Patients in trials did report reduced appetite and some weight movement during the titration phase. The GLP-1 receptor agonist mechanism (slowing the emptying of the stomach, increasing the sensation of fullness, modulating hunger signals in the brain) is operating at every dose. It simply intensifies as the dose increases.

If you are curious how 1mg compares to the starting dose in practical terms, our page on whether the lowest Wegovy dose works puts the 0.25mg step into context. Both sit within the preparatory phase; neither was designed to deliver the full weight-loss response on its own.

The 1.7mg step that follows 1mg is a meaningful increase, and many patients notice a more pronounced appetite effect at that point. The 2.4mg maintenance dose is where the majority of clinical benefit in the STEP programme was seen.

Side effects at 1mg and what to expect as the dose rises

Gastrointestinal side effects, including nausea, loose stools, constipation and reflux, are generally most noticeable in the days after a dose step-up. By 1mg, many people find their system has adjusted compared to the first injection, though the next increase to 1.7mg can bring a brief reset. If you want to understand what that very first injection typically feels like before any adjustment has occurred, our page on whether the first dose of Wegovy works explains what most people experience at that earliest stage.

That pattern is expected and the slow titration schedule is explicitly designed to reduce it. Trying to move faster than the standard four-weekly progression usually produces more discomfort, not better results. Your prescriber can slow the pace if side effects are interfering significantly with daily life, that is a legitimate clinical reason to hold a dose for longer before increasing.

The side-effect profile for semaglutide at any dose is led by GI symptoms, and the NHS page on semaglutide covers which symptoms are common, which are less frequent, and what signs would need urgent medical attention. For general context on the Wegovy dosing pathway, our Wegovy doses overview describes what changes at each stage.

What staying at 1mg for longer than planned means

Sometimes people stay at 1mg beyond the standard four weeks, because a dose increase was delayed, because a side effect needed time to settle, or because supply of the next pen was briefly disrupted. That is not unusual and it does not undo earlier progress.

Holding a dose does mean the titration takes longer to reach maintenance, which may push back when the greatest weight-loss effect is felt. It does not mean the medicine has failed. Prescribers assess this individually; the right pace varies by person. It can also help to revisit the early part of the journey, and our page looking at whether 0.25mg Wegovy works gives useful background on why even the smallest dose plays a genuine role in the overall plan.

If you are weighing up what Wegovy can realistically achieve across the full treatment course, the page examining at what dose Wegovy works puts the full dose range in evidence-based perspective. And if you are still building your understanding of the broader treatment landscape, our weight-loss treatments overview sets out the options available through a clinical consultation.

For those thinking about access through a clinically regulated route, a free consultation with our clinical team is the right starting point, a prescriber reviews your situation personally and can advise on whether Wegovy is suitable and how the dose plan fits your needs. Speak to our prescribers if you would like to explore whether Wegovy is the right choice for you.